New clinical trial

[Farooqji]

New clinical trial registered: 18-month study evaluating efficacy, safety, tolerability & pharmacokinetics of oral UCB0599 (alpha-synuclein misfolding inhibitor from

ucb_news

under license from Neuropore Therap) in individuals with early-stage ParkinsonsThis is a double-blind, placebo-controlled, randomized Phase 2a study of 300 individuals; Primary endpoint=UPDRS Parts I-III; Study finishing in October 2023

clinicaltrials.gov/ct2/show...